MA34654B1 - Variants silencieux de fc d'anticorps anti-cd40 - Google Patents

Variants silencieux de fc d'anticorps anti-cd40

Info

Publication number
MA34654B1
MA34654B1 MA35885A MA35885A MA34654B1 MA 34654 B1 MA34654 B1 MA 34654B1 MA 35885 A MA35885 A MA 35885A MA 35885 A MA35885 A MA 35885A MA 34654 B1 MA34654 B1 MA 34654B1
Authority
MA
Morocco
Prior art keywords
antibodies
silent variants
silent
variants
transplant
Prior art date
Application number
MA35885A
Other languages
English (en)
Inventor
Christoph Heusser
James Rush
Karen Vincent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34654(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA34654B1 publication Critical patent/MA34654B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des variants silencieux de FC d'anticorps anti-CD40 et des compositions et des procédés d'utilisation desdits anticorps pour le traitement de troubles pathologiques, tels que des troubles auto-immuns et inflammatoires et/ou pour la prévention ou la réduction du risque du rejet de greffe dans une transplantation.
MA35885A 2010-11-15 2013-05-07 Variants silencieux de fc d'anticorps anti-cd40 MA34654B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15
PCT/EP2011/070058 WO2012065950A1 (fr) 2010-11-15 2011-11-14 Variants silencieux de fc d'anticorps anti-cd40

Publications (1)

Publication Number Publication Date
MA34654B1 true MA34654B1 (fr) 2013-11-02

Family

ID=44925566

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35885A MA34654B1 (fr) 2010-11-15 2013-05-07 Variants silencieux de fc d'anticorps anti-cd40

Country Status (39)

Country Link
US (8) US8828396B2 (fr)
EP (4) EP4023676A1 (fr)
JP (1) JP5782132B2 (fr)
KR (1) KR101632775B1 (fr)
CN (2) CN105949314B (fr)
AR (2) AR083847A1 (fr)
AU (1) AU2011331288B2 (fr)
BR (1) BR112013011644B1 (fr)
CA (1) CA2815921C (fr)
CL (1) CL2013001124A1 (fr)
CO (1) CO6801629A2 (fr)
CR (1) CR20130222A (fr)
CU (1) CU24057B1 (fr)
CY (2) CY1119097T1 (fr)
DK (2) DK3502138T3 (fr)
EA (1) EA026133B1 (fr)
ES (2) ES2911460T3 (fr)
GT (1) GT201300128A (fr)
HR (2) HRP20220413T1 (fr)
HU (2) HUE058015T2 (fr)
IL (1) IL225719A (fr)
JO (1) JO3266B1 (fr)
LT (2) LT3502138T (fr)
MA (1) MA34654B1 (fr)
MX (1) MX336633B (fr)
MY (1) MY159316A (fr)
NZ (1) NZ609549A (fr)
PE (1) PE20140979A1 (fr)
PH (1) PH12013500973A1 (fr)
PL (2) PL3502138T3 (fr)
PT (2) PT3502138T (fr)
RS (2) RS56153B1 (fr)
SG (1) SG189928A1 (fr)
SI (2) SI3502138T1 (fr)
TW (2) TWI531581B (fr)
UA (1) UA112417C2 (fr)
UY (2) UY39292A (fr)
WO (1) WO2012065950A1 (fr)
ZA (1) ZA201302532B (fr)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3153526B1 (fr) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Anticorps anti cd39 humaine et leur utilisation pour l'inhibition de l'activité des lymphocytes t de régulation
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
ES2734076T3 (es) * 2011-02-17 2019-12-04 Kyowa Hakko Kirin Co Ltd Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
NO2699601T3 (fr) 2011-04-21 2018-06-16
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
CA2888763A1 (fr) 2012-10-30 2014-05-08 Apexigen, Inc. Anticorps anti-cd40 et procedes d'utilisation
MX366978B (es) 2013-03-15 2019-08-01 Novartis Ag Conjugados de anticuerpo - farmaco.
WO2015134988A1 (fr) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
WO2016020791A1 (fr) 2014-08-05 2016-02-11 Novartis Ag Conjugués anticorps ckit-médicament
MX2017001946A (es) 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
WO2016055609A1 (fr) 2014-10-10 2016-04-14 Innate Pharma Blocage de cd73
WO2016094679A1 (fr) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Cellules, tissus et organes génétiquement modifiés pour le traitement d'une maladie
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (fr) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Liquide de transmission de pression pour analyseur cellulaire, analyseur cellulaire et procédé d'analyse d'un échantillon cellulaire liquide
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗ｃｄ４０抗体およびその使用
WO2017040932A1 (fr) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Anticorps humanisés anti-cd40 et leurs utilisations
CN107969127B (zh) * 2015-09-08 2022-09-06 赛瑞品股份有限公司 Apoa-1融合多肽及相关组合物和方法
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
PE20181367A1 (es) * 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
WO2017064043A1 (fr) 2015-10-12 2017-04-20 Innate Pharma Agents de blocage de cd73
BR112018015272A2 (pt) 2016-02-10 2018-12-18 Novartis Ag uso de inibidores da atividade ou função de pi3k para o tratamento de síndrome de sjögren primária
CN108699158B (zh) 2016-03-08 2022-06-03 依奈特制药公司 Siglec中和抗体
WO2017157948A1 (fr) 2016-03-14 2017-09-21 Innate Pharma Anticorps anti-cd39
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018065552A1 (fr) 2016-10-06 2018-04-12 Innate Pharma Anticorps anti-cd39
WO2018083080A2 (fr) 2016-11-04 2018-05-11 Innate Pharma Ligand de nkp46
CA3045944A1 (fr) 2016-12-07 2018-06-14 Progenity, Inc. Procedes, dispositifs et systemes de detection du tractus gastro-intestinal
AU2018213823B2 (en) 2017-01-24 2024-11-07 Innate Pharma NKp46 binding agents
WO2018141959A1 (fr) 2017-02-06 2018-08-09 Innate Pharma Conjugués médicament anticorps immunomodulateurs se liant à un polypeptide mica humain
AU2018235092B2 (en) 2017-03-16 2024-09-19 Innate Pharma Compositions and methods for treating cancer
CN110582264B (zh) * 2017-03-26 2022-11-11 V·R·斯塔福德 眼睑皮肤状况的处理方法
CA3054632A1 (fr) 2017-03-30 2018-10-04 Progenity, Inc. Traitement d'une maladie du tractus gastro-intestinal avec un agent immunomodulateur libere a l'aide d'un dispositif ingerable
WO2018185618A1 (fr) 2017-04-03 2018-10-11 Novartis Ag Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
US20200148779A1 (en) * 2017-05-25 2020-05-14 Bristol-Myers Squibb Company MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
CN110506058A (zh) * 2017-06-02 2019-11-26 豪夫迈·罗氏有限公司 免疫激动剂的施用路径
CN111263769B (zh) 2017-07-10 2024-01-02 先天制药公司 Siglec-9中和性抗体
WO2019011852A1 (fr) 2017-07-10 2019-01-17 Innate Pharma Polythérapie utilisant un anticorps dirigé contre siglec-9 humain et anticorps dirigé contre nkg2a humain pour le traitement du cancer
WO2019057792A1 (fr) * 2017-09-19 2019-03-28 Mab Discovery Gmbh Anticorps cd40 agonistes
EP3704158A1 (fr) * 2017-11-03 2020-09-09 Novartis AG Anticorps anti-cd40 destinés à être utilisés dans le traitement du syndrome de sjögren
CN111417651B (zh) 2017-12-01 2023-09-29 诺华股份有限公司 多瘤病毒中和抗体
JP6861301B2 (ja) * 2018-04-13 2021-04-21 ノバルティス アーゲー 移植片拒絶の予防に使用するための抗ｃｄ４０抗体
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
CN119490583A (zh) 2018-05-31 2025-02-21 诺华股份有限公司 乙型肝炎抗体
WO2019241730A2 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
TWI870353B (zh) 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
WO2020053742A2 (fr) 2018-09-10 2020-03-19 Novartis Ag Anticorps peptidiques anti-hla-vhb
CN113348011B (zh) 2018-11-19 2023-04-18 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
TW202039554A (zh) 2018-12-19 2020-11-01 瑞士商諾華公司 抗ＴＮＦ－α抗體
CN113330033B (zh) 2018-12-26 2024-11-29 先天制药公司 白细胞免疫球蛋白样受体2中和性抗体
US12435150B2 (en) * 2019-01-11 2025-10-07 Novartis Ag Anti-CD40 antibodies for use in treatment of hidradenitis suppurativa
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
AU2020267953A1 (en) 2019-05-08 2021-11-18 Novartis Ag Anti-CD40 antibodies for use in treatment of T1DM and insulitis
JP7137696B2 (ja) 2019-05-14 2022-09-14 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を予防するための方法および組成物
PH12021553101A1 (en) 2019-06-12 2023-10-02 Novartis Ag Natriuretic peptide receptor 1 antibodies and methods of use
DK3993876T3 (en) * 2019-07-01 2024-12-02 Tonix Pharma Ltd Anti-cd154 antibodies and uses thereof
MX2022003009A (es) * 2019-09-11 2022-06-14 Novartis Ag Metodo para prevenir trastornos asociados a virus humanos en pacientes.
US20220348632A1 (en) 2019-09-18 2022-11-03 Novartis Ag Nkg2d fusion proteins and uses thereof
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2021152175A1 (fr) * 2020-01-31 2021-08-05 Sanofi Administration pulmonaire d'anticorps
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
KR20230050378A (ko) 2020-08-13 2023-04-14 이나뜨 파르마 에스.에이. 항-cd73 항체를 사용하여 암을 치료하는 방법
JP2023538105A (ja) * 2020-08-21 2023-09-06 ウーシー・バイオロジクス・（シャンハイ）・カンパニー・リミテッド Ｃｄ４０アゴニスト抗体及び使用方法
WO2022040586A2 (fr) 2020-08-21 2022-02-24 Novartis Ag Compositions et méthodes pour la génération in vivo de cellules exprimant car
WO2022097065A2 (fr) 2020-11-06 2022-05-12 Novartis Ag Variants fc d'anticorps
EP4259661A1 (fr) 2020-12-14 2023-10-18 Novartis AG Agents d'inversion de liaison pour anticorps anti-récepteur 1 du peptide natriurétique (npr1) et leurs utilisations
WO2022164818A2 (fr) * 2021-01-26 2022-08-04 The Regents Of The University Of California Prévention de l'opacification de la capsule postérieure (pco) avec un anticorps bloquant l'intégrine avb8
CA3202891A1 (fr) * 2021-01-28 2022-08-04 Kara Olson Compositions et methodes de traitement du syndrome de liberation de cytokines
EP4313109A1 (fr) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
EP4365200A4 (fr) * 2021-06-28 2025-04-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticorps anti-cd40, fragment de liaison à l'antigène et son utilisation médicale
US20240316104A1 (en) 2021-06-29 2024-09-26 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
EP4388000A1 (fr) 2021-08-20 2024-06-26 Novartis AG Procédés de fabrication de cellules exprimant un récepteur antigénique chimérique
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
CN118234749A (zh) 2021-09-17 2024-06-21 诺华股份有限公司 用于预防异种移植中的移植物排斥的方法
WO2023046037A1 (fr) 2021-09-24 2023-03-30 正大天晴药业集团股份有限公司 Anticorps anti-cd40 et son utilisation
US20240392026A1 (en) 2021-10-01 2024-11-28 Mab Discovery Gmbh Agonistic cd40 antibodies as immune stimulatory agents
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
JP2025510997A (ja) 2022-03-30 2025-04-15 ノバルティス アーゲー 抗ナトリウム利尿ペプチド受容体１（ｎｐｒ１）抗体を使用して障害を治療する方法
KR20250067174A (ko) 2022-09-15 2025-05-14 노파르티스 아게 키메라 항원 수용체 요법을 사용한 자가면역 장애의 치료
WO2024077191A1 (fr) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024140917A1 (fr) * 2022-12-28 2024-07-04 上海盛迪医药有限公司 Conjugué anticorps-médicament anti-cd40, son procédé de préparation et son utilisation médicale
WO2024151687A1 (fr) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Commutateurs génétiques et leur utilisation dans le traitement du cancer
EP4727973A1 (fr) 2023-06-16 2026-04-22 Regeneron Pharmaceuticals, Inc. Molécules de liaison à l'antigène bispécifiques cd40 x cd40 et leurs utilisations
WO2025023895A1 (fr) * 2023-07-26 2025-01-30 Db Biotech, A.S. Anticorps dirigé contre le composant c4d du complément
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025184567A1 (fr) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Procédés et compositions pour redosage d'un aav à l'aide d'un anticorps antagoniste anti-cd40 pour supprimer une réponse d'anticorps anti-aav hôte
WO2025233264A1 (fr) 2024-05-07 2025-11-13 Innate Pharma Utilisation d'agents bloquant le cd73 en association avec des engageurs de lymphocytes t anti-cd20 x cd3
WO2025233266A1 (fr) 2024-05-07 2025-11-13 Innate Pharma Utilisation d'agents bloquant le cd39 en association avec des engageurs de lymphocytes t anti-cd20 x cd3
WO2026082692A1 (fr) * 2024-10-15 2026-04-23 Les Laboratoires Servier Anticorps dirigés contre cd40, et compositions associées

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766A (en) 1846-09-19 Stbaw-cutter
US106A (en) 1915-08-24 Specipication
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
CA1294215C (fr) 1986-10-27 1992-01-14 Ze'ev Shaked Compositions pharmaceutiques d'interferon beta recombinant et methodes de formulation
CA1292686C (fr) 1986-10-27 1991-12-03 Ze'ev Shaked Compositions pharmaceutiques d'interleukine-2 recombinante et procede de fabrication
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
FI961285L (fi) 1993-10-01 1996-03-20 Immunex Corp CD40:n vasta-aineita
DE69433820T2 (de) 1993-12-23 2005-06-23 Immunex Corp., Seattle Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
CA2184356A1 (fr) 1994-03-03 1995-09-08 Russell P. Rother Genes et proteines de fusion inhibant le complement terminal
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
CA2226575C (fr) 1995-07-27 2011-10-18 Genentech, Inc. Formulation de proteine lyophilisee isotonique et stable
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
EP1034001B1 (fr) 1997-06-20 2004-08-04 Biogen Idec MA Inc. Therapie par blocage des cellules cd154 contre le syndrome inhibiteur de proteines therapeutiques
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2001034649A2 (fr) 1999-11-09 2001-05-17 Chiron Corporation Compositions et methodes de traitement de maladies auto-immunes et des rejets de greffon
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (fr) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
JP2004502742A (ja) 2000-07-12 2004-01-29 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞を消滅させる抗体及び免疫調節抗体を併用するｂ細胞悪性疾患の治療関連出願
WO2002022212A2 (fr) 2000-09-18 2002-03-21 Idec Pharmaceuticals Corporation Polytherapie pour le traitement de maladies auto-immunes utilisant une combinaison d'anticorps d'immunoregulation/de depletion de cellules b
WO2002028481A2 (fr) 2000-10-02 2002-04-11 Chiron Corporation Methodes therapeutiques pour lutter contre les cellules b malignes
CA2436180C (fr) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Anticorps immunoregulateurs et ses utilisations
JP4679035B2 (ja) 2001-04-02 2011-04-27 ジェネンテック， インコーポレイテッド 併用療法
CA2658221C (fr) 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anticorps monoclonal anti-cd40
WO2003029296A1 (fr) 2001-10-02 2003-04-10 Chiron Corporation Anticorps humains diriges contre le cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002346581A1 (en) 2001-11-26 2003-06-10 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
CN103040732B (zh) 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
AU2004287879C1 (en) * 2003-11-04 2011-05-26 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-CD40 monoclonal antibodies and methods for their use
PT1684805E (pt) 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
US20070098718A1 (en) 2003-11-04 2007-05-03 Chiron Methods of therapy for b cell-related cancers
DK1680141T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
EP1707627B1 (fr) 2003-12-25 2012-11-14 Kyowa Hakko Kirin Co., Ltd. Mutant antagonistique d'un anticorps anti-CD40
RU2006141632A (ru) 2004-04-27 2008-06-10 Новартис Вэксинес Энд Дайэгностикс, Инк. (Us) Антагонистические моноклональные анти-cd40-антитела и способы их применения
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP2312315A1 (fr) 2005-05-18 2011-04-20 Novartis AG Procédés pour le diagnostic et le traitement des maladies ayant une composante auto-immune et/ou inflammatoire
WO2007053661A2 (fr) 2005-11-01 2007-05-10 Novartis Ag Utilisations d'anticorps anti-cd40
US7812133B2 (en) * 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
EP1854810A1 (fr) 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
AU2007319672B2 (en) * 2006-06-06 2011-06-30 Genentech, Inc. Anti-DLL4 antibodies and methods using same
CA2682406A1 (fr) * 2007-04-02 2008-10-09 Genentech, Inc. Marqueurs biologiques predictifs de la reaction de la polyarthrite rhumatoide aux antagonistes de lymphocytes b
TW201446265A (zh) * 2007-04-02 2014-12-16 建南德克公司 克羅梭（ｋｌｏｔｈｏ）ｂｅｔａ調節劑之用途
CA2693053C (fr) * 2007-05-30 2021-01-05 Xencor, Inc. Procedes et compositions permettant l'inhibition de cellules d'expression du cd32b
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP5694921B2 (ja) * 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
WO2014139023A1 (fr) 2013-03-15 2014-09-18 Synaptive Medical (Barbados) Inc. Système de positionnement intelligent et procédés y relatifs

Also Published As

Publication number Publication date
AU2011331288B2 (en) 2014-09-11
TWI531581B (zh) 2016-05-01
CR20130222A (es) 2013-06-28
US20120121585A1 (en) 2012-05-17
KR20130080856A (ko) 2013-07-15
PL2640749T3 (pl) 2017-09-29
CN105949314A (zh) 2016-09-21
EP3502138B9 (fr) 2022-03-09
CA2815921A1 (fr) 2012-05-24
CN103209996A (zh) 2013-07-17
CN103209996B (zh) 2016-07-20
SI3502138T1 (sl) 2022-05-31
ZA201302532B (en) 2014-09-25
UY39292A (es) 2021-07-30
SI2640749T1 (sl) 2017-07-31
US9828433B2 (en) 2017-11-28
UY33728A (es) 2012-06-29
DK2640749T3 (en) 2017-07-31
LT2640749T (lt) 2017-07-10
TW201305208A (zh) 2013-02-01
EP3222636A1 (fr) 2017-09-27
CY1119097T1 (el) 2018-01-10
US20160152721A1 (en) 2016-06-02
IL225719A0 (en) 2013-06-27
CY1125252T1 (el) 2024-12-13
TW201623335A (zh) 2016-07-01
AR122999A2 (es) 2022-10-19
JP2014500720A (ja) 2014-01-16
SG189928A1 (en) 2013-06-28
PT3502138T (pt) 2022-04-06
CU20130071A7 (es) 2013-09-27
US20240228640A9 (en) 2024-07-11
DK3502138T3 (da) 2022-04-19
KR101632775B1 (ko) 2016-06-22
US10323096B2 (en) 2019-06-18
US9688768B2 (en) 2017-06-27
CO6801629A2 (es) 2013-11-29
US11124578B2 (en) 2021-09-21
CN105949314B (zh) 2021-04-09
LT3502138T (lt) 2022-04-11
HRP20220413T1 (hr) 2022-05-27
AR083847A1 (es) 2013-03-27
GT201300128A (es) 2015-06-02
MX2013005477A (es) 2013-06-12
ES2911460T3 (es) 2022-05-19
CL2013001124A1 (es) 2014-07-04
MY159316A (en) 2016-12-30
EP3502138B1 (fr) 2022-01-19
US8828396B2 (en) 2014-09-09
TWI608016B (zh) 2017-12-11
JO3266B1 (ar) 2018-09-16
PH12013500973A1 (en) 2013-07-08
US20140341898A1 (en) 2014-11-20
PE20140979A1 (es) 2014-08-09
US20200087409A1 (en) 2020-03-19
PL3502138T3 (pl) 2022-05-02
RS56153B1 (sr) 2017-11-30
AU2011331288A1 (en) 2013-05-02
HRP20171084T1 (hr) 2017-10-06
US20240132606A1 (en) 2024-04-25
US9221913B2 (en) 2015-12-29
HUE034203T2 (en) 2018-01-29
EP4023676A1 (fr) 2022-07-06
RS63094B1 (sr) 2022-04-29
US20170267772A1 (en) 2017-09-21
JP5782132B2 (ja) 2015-09-24
PT2640749T (pt) 2017-07-25
EA026133B1 (ru) 2017-03-31
NZ609549A (en) 2015-05-29
BR112013011644B1 (pt) 2022-02-22
IL225719A (en) 2017-09-28
UA112417C2 (uk) 2016-09-12
BR112013011644A2 (pt) 2016-08-02
US20220204635A1 (en) 2022-06-30
HUE058015T2 (hu) 2022-06-28
CU24057B1 (es) 2014-12-26
EP2640749A1 (fr) 2013-09-25
CA2815921C (fr) 2021-07-06
WO2012065950A1 (fr) 2012-05-24
EA201390725A1 (ru) 2013-09-30
EP3502138A1 (fr) 2019-06-26
MX336633B (es) 2016-01-26
ES2633817T3 (es) 2017-09-25
EP2640749B1 (fr) 2017-04-19
US20180118843A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
PH12013500973A1 (en) Silent fc variants of anti-cd40 antibodies
MA35661B1 (fr) Inhibiteurs de pak pour le traitement de troubles de prolifération cellulaire
MA31667B1 (fr) Induction dun phenotype tolerogene dans des cellules dendritiques matures
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
MA31795B1 (fr) Molécules et méthodes pour moduler un constituant de complément
MA32035B1 (fr) Composes tricycliques servant de modulateurs de synthese de tnf-alpha et d'inhibiteurs de pde4
MA34248B1 (fr) 5-fluoro-1h-pyrazolopyridines substituées et leur utilisation
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA34641B1 (fr) Anticorps anti-il-23
MA34263B1 (fr) Marqueurs de prédiction utiles dans traitement du syndrome de l'x fragile (fxs)
MX349463B (es) Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
MA45504B1 (fr) Utilisation d'inhibiteurs de télomérase pour le traitement de troubles myéloprolifératifs et de néoplasies myéloprolifératives
EP2571360A4 (fr) Méthodes et formulations pour le traitement par l'oxytocine de troubles liés à l'utilisation de substances toxiques, de troubles psychiatriques et autres troubles
EP2493930A4 (fr) Compositions et méthodes pour le traitement de troubles inflammatoires
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
EP2631220A4 (fr) Dispositif de traitement pour des déchets tels que des boues
EP2766012A4 (fr) Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
MA34541B1 (fr) Compositions d'anticorps et procédés d'utilisation
MA20150279A1 (fr) (r)-nifuratel, son utilisation pour le traitement d'infections et synthèse de (r) et (s)-nifuratel
MA37946B1 (fr) Utilisation d’un anticorps anti-gm-csf pour le traitement de la polyarthrite rhumatoïde
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
TN2011000669A1 (fr) L-serine pour son utilisation en tant que medicament pour prevenir et/ou traiter une reaction inflammatoire de la peau
MA34827B1 (fr) Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes